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Burden of disease and circulating serotypes of rotavirus 
infection in sub-Saharan Africa: systematic review and 
meta-analysis
Elisabeth Sanchez-Padilla, Rebecca F Grais, Philippe J Guerin, Andrew D Steele, Marie-Eve Burny, Francisco J Luquero
Two new rotavirus vaccines have recently been licensed in many countries. However, their eﬃ   cacy has only been 
shown against certain serotypes commonly circulating in Europe, North America, and Latin America, but thought 
to be globally important. To assess the potential impact of these vaccines in sub-Saharan Africa, where rotavirus 
mortality is high, knowledge of prevalent types is essential because an eﬀ  ective rotavirus vaccine is needed to 
protect against prevailing serotypes in the community. We did two systematic reviews and two meta-analyses of 
the most recent published data on the burden of rotavirus disease in children aged under 5 years and rotavirus 
serotypes circulating in countries in sub-Saharan Africa. Eligible studies were selected from PubMed/Medline, 
Cochrane Library, EmBase, LILACS, Academic Search Premier, Biological Abstracts, ISI Web of Science, and the 
African Index Medicus. Depending on the heterogeneity, DerSimonian–Laird random-eﬀ  ects or ﬁ  xed-eﬀ  ects 
models were used for meta-analyses. Geographical variability in rotavirus burden within countries in sub-Saharan 
Africa is substantial, and most countries lack information on rotavirus epidemiology. We estimated that annual 
mortality for this region was 243·3 (95% CI 187·6–301·7) deaths per 100 000 under 5 years (ie, a total of 300 000 
children die of rotavirus infection in this region each year). The most common G type detected was G1 (34·9%), 
followed by G2 (9·1%), and G3 (8·6%). The most common P types detected were P[8] (35·5%) and P[6] (27·5%). 
Accurate information should be collected from surveillance based on standardised methods in these countries to 
obtain comparable data on the burden of disease and the circulating strains to assess the potential impact of 
vaccine introduction.
Introduction
Two large clinical trials, published in January, 2006, 
assessed the eﬃ   cacy and safety of two rotavirus vaccines 
in infants.
1,2 Both vaccines are currently prequaliﬁ  ed by 
WHO and their introduction into national 
immunisation programmes has recently been 
recommended.
3 Rotaviruses are the leading cause of 
severe diarrhoeal disease and dehydration in infants 
and young children in high-income and low-income 
countries.
4 The virus is composed of three protein 
shells: an outer and an inner capsid, and an internal 
shell that encases the 11-segment double-stranded RNA 
genome. The inner capsid protein (VP6) allows the 
classiﬁ   cation into various groups, of which three 
groups (A–C) are known to include human rotaviruses. 
Nearly all of the commonly detected rotaviruses that 
aﬀ   ect human beings belong to group A.
5 The two 
structural outer capsid proteins, VP7 (G glycoprotein) 
and VP4 (P protein) deﬁ  ne the G and P serotypes of the 
virus, respectively. These major antigens are involved 
in virus neutralisation, and hence elicit the production 
of neutralising antibodies in the host and are thought 
to be important for vaccine development. These 
antigens allow the classiﬁ  cation of rotaviruses into a 
dual nomenclature system, depending on the G–P 
antigen combination (eg, G1P[8] or G2P[4]).
The new rotavirus vaccines have proven eﬃ   cacy 
against some human rotavirus serotypes. Rotarix 
(GlaxoSmithKline Biologicals, Rixensart, Belgium) has 
been shown to be eﬀ  ective in the prevention of severe 
rotavirus gastroenteritis caused by G1P[8], G3P[8], 
G4P[8], and G9P[8].
1 Rotateq (Merck Co, Whitehouse 
Station, NJ, USA) has also proven to be eﬀ  ective in the 
prevention of hospital admissions and visits to the 
emergency department due to rotavirus strains G1, G3, 
G4, and G9.
2 Limited data also exists on eﬃ   cacy against 
G2 strains for both vaccines. To assess the expected 
impact of the vaccine introduction, knowledge of 
prevalent types is essential because an eﬀ  ective rotavirus 
vaccine should protect against prevailing serotypes in 
the community. 
Recent estimates show that serotypes G1, G3, G4, and 
G9 account for 90% of all rotavirus infections in North 
America and Europe; however, these serotypes are 
responsible for less than 70% of cases in Africa.
6 Whereas 
P[8] and P[4] account for over 90% of P types circulating 
worldwide, the relative frequency of these two serotypes 
seems to be lower in Africa, where P[6] accounts for 
almost a third of all P types detected.
6 
Countries in sub-Saharan Africa have a higher burden 
of diarrhoeal diseases and rotavirus-related deaths than 
the rest of the world.
7,8 Although rotavirus is recognised 
as the most important causal agent implicated in severe 
diarrhoea in young children, summarised information 
available on its epidemiology in sub-Saharan Africa is 
limited to 19 studies from nine countries, mostly from 
eastern and southern Africa.
6,9 
We did two systematic reviews and two meta-analyses 
of the most recent published data on the burden 
of rotavirus disease in children aged under 5 years and 
on rotavirus serotypes circulating in countries in 
sub-Saharan Africa.
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Methods
Search strategy and selection criteria
We systematically searched PubMed/Medline, Cochrane 
Library, EmBase, LILACS, Academic Search Premier, 
Biological Abstracts, ISI Web of Science, and the African 
Index Medicus for articles published from January, 1990, 
to April, 2009, in English, French, Italian, Portuguese, or 
Spanish. We searched using the terms “rotavirus” and the 
name of the country. All countries in sub-Saharan Africa, 
as deﬁ  ned by the United Nations Educational, Scientiﬁ  c 
and Cultural Organisation were searched individually.
10
The list of publications obtained through this search 
was narrowed to studies thought to be relevant to disease 
burden and serotype circulation. Retrieved studies had to 
report either the proportion of rotavirus disease among 
children with acute diarrhoea, or G type, P type, or both 
characterisation of circulating rotavirus. Studies meeting 
both criteria were included in both reviews.
Studies based only on preterm infants or neonates, on 
asymptomatic or immunocompromised children, on 
children aged older than 5 years, or limited to outbreaks 
or to hospital-acquired infections were excluded. In 
addition, to quantify the burden of rotavirus disease, 
studies lasting less than 12 months or including fewer 
than 100 children were excluded. 
Data abstraction and quality assessment
Two reviewers (ESP and FJL) independently extracted 
data from the detected studies. We gathered the following 
information from every study: country, study duration, 
deﬁ   nition of diarrhoea, inclusion criteria, represen-
tativeness and precision of the estimates, age-group, 
setting (community, outpatient department, or hospital 
based), number of samples tested, number of rotavirus-
positive samples, typing method (if any), number of 
samples typed, and number of positive samples for each 
G and P type. Data were entered into a Microsoft Oﬃ   ce 
Excel database by the two reviewers (ESP and FJL). 
Diﬀ   erences in the data extracted were resolved by 
discussion with a third reviewer (RFG). We included 
cross-sectional and cohort studies. Studies reported from 
the same country were cross-referenced by location and 
time period to avoid data duplication. 
Burden of rotavirus disease
We did a meta-analysis to obtain a point proportion of 
diarrhoea due to rotavirus for each country for which 
data was available and for all sub-Saharan Africa by age-
group. We used ﬁ  xed-eﬀ  ects models or the DerSimonian–
Laird random-eﬀ  ects  methods,
11 depending on the 
heterogeneity of the studies, on the basis of Cochran’s 
Q-test. The variances of the raw proportions given in 
each study were stabilised using a Freeman–Tukey-type 
arcsine square-root transformation (y=arcsine[√(r/
(n+1))]+arcsine[√(r/(n+1)/(n+1)]), with a variance of 
1/(n+1), where n is the population size.
12 We calculated 
the  I
2 statistic as a measure of the proportion of the 
overall variation in the proportion that was attributable to 
between-study heterogeneity. We also did a stratiﬁ  ed 
analysis to assess the weight of rotavirus infection on 
diarrhoeal disease according to age and setting of the 
study (community, outpatient department, or hospital 
based). If there was only one study in the country, we 
calculated the 95% CI by use of the exact test of Clopper–
Pearson.
13
To calculate the mortality rate due to rotavirus, we 
followed the same methods published previously for 
obtaining global estimates of rotavirus deaths,
8,14 and 
recommended by WHO.
15 By country and for all sub-
Saharan Africa, we multiplied the population aged under 
5 years by the mortality in this age-group to obtain the 
86 potentially relevant studies identiﬁed
73 studies reporting proportion of 
rotavirus disease among children 
with acute diarrhoea
32 studies reporting G-type and/or 
P-type characterisation of 
circulating rotavirus
31 articles included in meta-analysis of
circulating genotype or serotypes 
(39 studies)
35 articles included in meta-analysis of
burden of disease (44 studies)
38 studies excluded 
1 nosocomial
21 <100 samples analysed
16 <12 months duration
1 study excluded 
1 neonates or preterm 
    infants
165 references excluded
60 did not address the search question
31 not related to SSA
5 case reports
64 described non-human research
5 conferences, symposium, meetings
104 abstracts excluded
77 not relevant
3 reported outbreaks ﬁgures
2 nosocomial
7 neonates or preterm infants
3 asymptomatic
6 adults
2 not based in SSA
4 reviews
27 studies excluded
19 not relevant
1 not found
7 repeated data
113 potentially relevant studies identiﬁed
217 abstracts reviewed
382 references identiﬁed and screened
Figure 1: Flow diagram of articles and studies included in both parts of the analysis
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total number of deaths.
16 We then multiplied this number 
by the proportion of deaths due to diarrhoea 
(WHO country proﬁ  les) and by the combined proportion 
of diarrhoea hospital admissions due to rotavirus 
infection in children aged under 5 years (obtained 
through meta-analysis).
Circulating strains
The proportion of P genotypes and G serotypes or 
genotypes, non-typeable strains, and mixed infections 
were analysed independently. Again, the combined 
proportion of the diﬀ  erent genotypes or serotypes for 
each country and for all sub-Saharan Africa was calculated 
using ﬁ  xed-eﬀ   ects models or the DerSimonian–Laird 
random-eﬀ  ects method, depending on the heterogeneity 
of the studies, as explained above. All analyses were done 
with the statistical software R (version 2.7.2).
Results
Our search identiﬁ  ed 382 articles that were relevant to 
the objectives of this review. We excluded 335 articles 
according to the exclusion criteria. One article reported 
the results of 15 diﬀ  erent studies done in 12 countries in 
sub-Saharan Africa.
17 No additional studies were identiﬁ  ed 
through citations in articles. Figure 1 summarises the 
selection process and shows the number of articles 
included in both parts of the review. 35 articles (44 studies) 
were analysed for the burden of rotavirus disease and 
31 articles (39 studies) for the circulating strains.
17–70 
Characteristics of the patient population, study design, 
setting, and severe diarrhoea deﬁ  nition diﬀ  ered among the 
included studies, and typing method varied widely 
(webappendix).
17–70 The studies were done between 1984 
and 2007, and the median starting date was 1997 
(IQR 1991–99). Deﬁ  nition of acute diarrhoea was missing 
for 14 of 35 articles reporting data on burden of disease, 
and the selection criteria was absent in 22 of these studies. 
The age range used as inclusion criteria varied among 
studies, and the categories used to report the proportion of 
rotavirus diarrhoea by age-group also varied substantially. 
Samples were screened by EIA or ELISA in 35 studies, and 
with latex agglutination in four studies.
17,18,31,46 Polyacrylamide 
gel electrophoresis was used in two studies, either 
combined with ELISA and electron microscopy,
30 or only 
with ELISA.
47 One study used both ELISA and electron 
microscopy,
25 another ELISA and latex agglutination,
61 and 
one used electropherotyping.
53 Rotavirus type-G 
characterisation was done in 35 studies, in ﬁ  ve studies by 
ELISA,
25,47,57,59,64 in 27 studies by reverse-transcription PCR 
(RT-PCR), and in three studies by both techniques.
17,38,58 P-
type genotyping was done in 33 studies, all of which used 
RT-PCR (webappendix). 
Information was available on the proportion of rotavirus 
diarrhoea for 14 countries of 48 in the region (ﬁ  gure 2). 
The proportion of diarrhoea caused by rotavirus ranged 
between 0·6% for children aged under 2 years who were 
admitted to hospital in Mozambique
46 and 55·9% for 
children aged under 5 years who attended a hospital 
outpatient department in Nigeria.
53
In a stratiﬁ  ed analysis, by age and setting, meta-analysis 
showed that the highest proportion of diarrhoea 
attributable to rotavirus was in hospital-admitted children 
aged under 1 year (table 1). The lowest proportion was 
observed in community-based studies that included 
A B Burden of disease Circulating strains
Figure 2: Countries with published information on burden of rotavirus disease (A) and circulating rotavirus strains (B)
Sub-Saharan Africa, 1990–2009. The following countries provided data on both burden and circulating strains: Botswana, Cameroon, Côte d’Ivoire, Ghana, Guinea 
Bissau, Kenya, Malawi, Namibia, Nigeria, South Africa, Zambia, and Zimbabwe. Benin and Mozambique provided data on burden only; Burkina Faso and Tanzania 
provided data on circulating strains only.
See Online for webappendix570  www.thelancet.com/infection   Vol 9   September 2009
Review
children aged under 3 years. Figure 3 shows a forest plot of 
the proportion of diarrhoea attributable to rotavirus by 
setting. 
In sub-Saharan Africa, the global estimate of the 
annual rotavirus mortality rate was 243·3 (95% CI 
187·6–301·7) deaths per 100  000 children aged under 
5 years. This ﬁ  gure corresponds to 308 579 deaths per 
year due to rotavirus in this age-group. Mortality 
estimates could be made for seven countries from 
which the proportion of hospital admissions due to 
rotavirus diarrhoea in children aged under 5 years was 
available. The rotavirus mortality rate ranged from 6·2 
(South Africa) to 301·0 (Nigeria) per 100 000 children-
years (table 2). The median annual rotavirus mortality 
rate for the included countries was 193·3 (IQR 
161·55–228·45) cases per 100  000 children younger 
than 5 years. The annual number of deaths due to 
rotavirus infection ranged from 323 in South Africa to 
71 144 in Nigeria.
Information on the circulating rotavirus strains was 
available for 14 countries (ﬁ   gure 2). Summary 
proportions for each genotype are shown in tables 3 
and 4. The most frequent G type detected was G1 
(34·9%), followed by G2 (9·1%), and G3 (8·6%). G8 
accounted for 3·3% of the infections, and G4 and G9 
represented 1·9% and 2·6% each. The combined 
summary proportion (random-eﬀ   ects) for genotypes 
G1–G4 and G9 was 68·4% (95% CI 62·3–74·3; I²=94%; 
p<0·001). G12 strains were found in two studies, one 
done in Ghana (3·5%; 5 of 142)
27 and the other in Malawi 
(5·5%; 30 of 546).
45 7·8% of the samples contained 
more than one G-type strain, and in 15·4% the G type 
remained unknown (table 3). 
The most frequent P types detected were P[8] (35·5%) 
and P[6] (27·5%). P[4] accounted for 7·3% of the samples, 
and other P types for less than 0·5% each. Mixed genotypes 
accounted for 5·6% of the P-typed strains. Genotypes P[1], 
P[2], P[12], and P[14] were detected in one study each: P[1] 
in Nigeria (0·9%; 1 of 110),
51 P[2] in Guinea Bissau (1·2%; 2 
of 167),
34 P[12] in South Africa (2·6%; 6 of 227),
62 and P[14] 
also in South Africa (2·1%; 11 of 525).
17 Untyped P types 
accounted for 15·5% of the samples (table 4). The most 
common genotypes that presented with mixed infections 
were G2 and G8, and P[6], P[4], and P[8]. 
Discussion
This study gathers the most recent published data on 
the burden of disease and the circulating strains of 
rotavirus in sub-Saharan Africa, and underscores the 
lack of information about rotavirus epidemiology in 
most of these countries. Rotavirus mortality rates vary 
widely within and between countries in sub-Saharan 
Africa from which information is available, as do the 
genotypes of circulating rotavirus strains. Our estimate 
that approximately 300 000 children aged under 5 years 
die of rotavirus infection in sub-Saharan Africa each 
year is higher than the most recent data provided by 
WHO (251  783 deaths per year).
71 The diﬀ  erence 
between these estimates is mainly due to the assumed 
percentage of diarrhoeal deaths attributable to rotavirus. 
We applied the summary proportion of rotavirus 
infection in hospital-admitted children aged under 
5 years who were suﬀ   ering from watery diarrhoea. 
However, the number of available studies to calculate 
this estimate was low, which means that imprecise 
estimates were used and substantial variations exist 
due to extreme values, as in the study by Mandomando 
and colleagues.
46 Therefore, even slight variations in 
the studies included can signiﬁ  cantly modify the global 
ﬁ  gures. Moreover, the reporting methods used are not 
standardised, which makes diﬃ   cult the classiﬁ  cation 
of studies by setting.
The most accepted estimates of global rotavirus 
disease burden are based on the proportion of rotavirus 
cases seen at each health-care setting.
4 Good knowledge 
of the health-seeking behaviour of patients with 
diarrhoea is needed to extrapolate the observed 
proportion in diﬀ   erent settings to obtain the global 
burden of this disease. This information is missing in 
several regions of the world, including sub-Saharan 
Africa. The most accepted estimates of global rotavirus 
burden in low-income countries
8,14 are based on the 
health-seeking behaviour seen in a Chilean cohort 
study,
72 but health-seeking behaviour is likely to vary 
between geographical regions, and the distribution of 
cases in the diﬀ   erent health-care settings varies 
substantially between Latin America and Africa. These 
limitations underscore the importance of not only 
gathering more information on rotavirus disease 
burden in sub-Saharan Africa, but ensuring that a 
Studies 
(n)
Samples 
(n)
Proportion of diarrhoea 
due to rotavirus 
infection (95% CI)
Test for 
heterogeneity 
(I
2)
Community based*
<3 years
35,36 2 2400 3·4% (2·6–4·1)† 55·8%
<5 years
31 1 196 6·6% (3·6–11·1)‡ ..
Outpatient department§
<1 year
42,47,53,54,55,70  6 1195 32·8% (21·0–45·7)¶ 95·1%
<2 years
17||,22,24,26,30,39,42,47,50,53–56,70 15 8413 27·1% (20·9–33·8)¶ 97·6%
<3 years
22,25,37,39,42,47,54,55,61 9 4366 23·1% (18·4–28·0)¶ 92·6%
<5 years
17**,19,21,22,30,37,39,42,45,47,48,50,53–56,59,60 20 9572 21·8% (18·5–25·2)¶ 93·8%
Hospital based
<1 year
41,63,65,66,69 5 2444 39·4% (31·8–47·3)¶ 93·0%
<2 years
17||,41,46,63,65,66,69 8 7549 28·0%†† (17·5–39·8)¶ 99·1%
<3 years
18,41,63,65,69 5 4309 37·5% (25·7–50·2)¶ 98·4%
<5 years
17||,18,41,45,52,53,63,69 9 6584 35·4% (27·3–43·9)¶ 97·9%
*No studies provided data for children in the age-groups <1 year and <2 years. †Fixed-eﬀ  ects model. ‡Exact (Clopper–
Pearson) estimate. §Studies may have included children who required subsequent hospital admission. ¶Random-
effects model. ||Two studies included. **Three studies included. ††In a sensitivity analysis, excluding the study with an 
outlier (0·6%; Mandomando et al
46), the summary proportion obtained was 34·1% (26·1–42·6), I
2=98·1%.
Table 1: Summary of diarrhoeal episodes attributable to rotavirus infection by age and setting in sub-
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standard method is used in data collection and reporting 
to produce robust estimates of public-health relevance. 
High heterogeneity was also seen in the reporting of 
circulating strains, and noteworthy geographic and 
time-dependent diﬀ   erences between countries were 
observed. RT-PCR was used by most of the studies, and 
although it is much more sensitive than serological 
methods, many strains remained untyped. Reasons for 
untyping could be because the correct primers were not 
used or because new or unusual genotypes were 
Community-based studies
Nakano (1990)31
Fischer (2002)35
Molbak (1994)36 
Overall
Test for heterogeneity: χ2=7·0, df=2 (p=0·03), I2=71·5%
Outpatient studies
Kasule (2003)19
Basu (2003)21
Esona (2003)22
Koulla-Shiro (1995)23
Akoua-Koﬃ (2007)37
Armah (2003)24
Armah (1995)25
Binka (2003)26
Armah (1994)30
Steele (Ghana; 2003)17
Nakata (1999)38
Saidi (1997)39
Kiulia (2006)42
Steele (Kenya; 2003)17
Cunliﬀe (2009)45
Steele (Namibia; 2003)17
Steele (2002)47
Audu (2002)48
Gomwalk (1993)50
Odimayo (2008)53
Gomwalk (1990)54
Aminu (2008)55
Adah (1997)56
Pennap (2000)59
Steele (Zaria, Nigeria; 2003)17
Steele (Jos, Nigeria; 2003)17
Steele (1998)60
Sebata (2001)61
Tswana SA (1990)70
Overall
Test for heterogeneity: χ2=967·5, df=28 (p<0·001), I2=97·1%
Hospital-based studies
Anagonou (1993)18
Steele (CÔte d’Ivoire2003)17
Nokes (2008)41
Cunliﬀe (2009)45
Salu (2003)52
Odimayo (2008)53
Steele (Lagos, Nigeria; 2003)17
Haﬀejee (1990)63
Bos (1992)65
Griﬃths (1992)66
Steele (South Africa; 2003)17
Mpabalwani (1995)69
Steele (Zambia; 2003)17
Overall*
Test for heterogeneity: χ2=468·5, df=12 (p<0·001), I2=97·4%
Samples testing 
positive 
(n/N)
13/196 
46/1181 
34/1219 
93/2596
 
43/249 
32/346 
195/890 
40/272 
179/642 
894/2205 
47/289 
677/1717 
67/447 
83/204 
317/1431 
69/428 
24/135 
93/538 
159/452 
53/530 
116/672 
101/287 
108/392 
93/187 
146/442 
156/869 
45/314 
61/375 
154/833 
160/849 
46/225 
389/1229 
52/219 
64/220 
136/479 
587/1954 
419/1070 
21/150 
74/112 
161/417 
616/1113 
85/252 
63/180 
488/1525 
256/1069 
381/1635 
6·6% (3·5–11·0)
3·9% (2·9–5·2)
2·8% (1·9–3·9)
4·0% (2·6–5·7)
17·3% (12·8–22·6)
  9·3% (6·5–12·9)
21·9% (19·2–24·8)
14·7% (10·7–19·5)
27·9% (24·5–31·5)
40·5% (38·4–42·6)
16·3% (12·2–21·1)
39·4% (37·1–41·8)
15·0% (11·8–18·7)
40·7% (33·9–47·8)
22·2% (20·1–24·4)
16·1% (12·7–19·9)
17·8% (11·8–25·3)
17·3% (14·2–20·8)
35·2% (30·8–39·8)
10·0% (7·6–12·9)
17·3% (14·5–20·4)
35·2% (29·7–41·0)
27·6% (23·2–32·3)
49·7% (42·3–57·1)
33·0% (28·6–37·6)
18·0% (15·5–20·7)
14·3% (10·6–18·7)
16·3% (12·7–20·4)
18·5% (15·9–21·3)
18·9% (16·3–21·7)
20·4% (15·4–26·3)
31·7% (29·1–34·4)
23·7% (18·2–29·9)
23·0% (19·3–27·0)
29·1% (23·2–35·6)
28·4% (24·4–32·7)
30·0% (28·0–32·1)
39·2% (36·3–42·2)
14·0% (8·9–20·6)
66·1% (56·5–74·8)
38·6% (33·9–43·5)
55·4% (52·4–58·4)
33·7% (27·9–39·9)
35·0% (28·0–42·5)
32·0% (29·7–34·4)
24·0% (21·5–26·7)
23·3% (21·3–25·4)
34·0% (28·1–40·0)
Proportion of 
rotavirus 
(95% CI) 
01 0 2 0 3 0 4 0 5 0
Percentage of cases due to rotavirus (%)
60 70 80 90 100
4599/17 668 
3351/10 176 
Figure 3: Forest plots of the proportion of diarrhoea cases due to rotavirus stratiﬁ  ed by setting 
Sub-Saharan Africa, 1990–2008. *Total estimate excludes Mandomando et al
46 (study considered an outlier). Combined estimates were obtained by use of 
DerSimonian–Laird random-eﬀ  ects models.572  www.thelancet.com/infection   Vol 9   September 2009
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present.
6 Information on the circulating strains is 
important to enable assessment of the potential impact 
of rotavirus vaccination; to be eﬀ   ective, the vaccine 
must protect against the most prevalent serotypes. As 
other studies have shown, the most common genotypes 
(G1–G4, P[8]) worldwide are underrepresented in 
countries in sub-Saharan Africa, and, by contrast, 
uncommon serotypes are more prevalent in this 
Studies 
(n)
Summary proportion by G type
G1 G2 G3 G4 G8 G9 Mixed Untyped
n, % (95% CI) n, % (95% CI) n, % (95% CI) n, % (95% CI) n, % (95% CI) n, % (95% CI) n, % (95% CI) n, % (95% CI)
Botswana
17,19,20 3 45, 42·9%* 
(1·3 to 93·6)
4, 5·7%* 
(0·2 to 18·1)
7, 9·1%† 
(2·8 to 15·4)
0, ·· 0, ·· 0, ·· 13, 16·0%* 
(0·0 to 55·9)
11, 14·9%† 
(7·1 to 22·7)
Burkina Faso
17 1 6, 16·2%‡ 
(6·2 to 32·0)
28, 75·7%‡ 
(58·8 to 88·2)
0, ·· 0, ·· 0, ·· 0, ·· 0, ·· 3, 8·1%‡ 
(1·7 to 21·9)
Cameroon
17§ 2 113, 47·0%* 
(28·7 to 65·7)
14, 3·0%* 
(0·1 to 14·0)
69, 26·3%† 
(21·0 to 31·7)
12, 2·7%* 
(0·1 to 12·0)
4, 1·6%† 
(0·1 to 3·2)
0, ·· 14, 3·0%* 
(0·1 to 14·0)
37, 16·0%* 
(7·0 to 27·9)
Côte d’Ivoire
17 1 64,  48·1%‡ 
(39·4 to 56·9)
4, 3·0%‡ 
(0·8 to 7·5)
0, ·· 0, ·· 8, 6·0%‡ 
(2·6 to 11·5)
0, ·· 22, 16·5%‡ 
(10·7 to 24·0)
35, 26·3%‡ 
(19·1 to 34·7)
Ghana
25–29 5 154, 22·4%* 
(0·1 to 67·0)
91, 18·3%* 
(3·7 to 40·6)
79, 17·6%* 
(1·8 to 44·5)
7, 1·6%* 
(0·0 to 5·6)
11, 1·2%* 
(0·0 to 4·2)
71, 5·0%* 
(0·0 to 20·6)
22, 6·6%* 
(2·0 to 13·7)
62, 11·8%* 
(3·6 to 23·8)
Guinea Bissau
32–34 3 29, 8·5%† 
(5·6 to 11·4)
112, 30·3%* 
(19·6 to 42·3)
3, 0·9%† 
(0·0 to 1·9)¶
2, 0·7%† 
(0·0 to 1·6)¶
28, 8·3%* 
(0·8 to 22·6)
0, ·· 101, 32·7%* 
(2·9 to 75·0)
72, 11·9%* 
(0·0 to 42·6)
Kenya
38,40 2 89,  45·4%* 
(10·3 to 83·4)
53, 10·0%* 
(0·2 to 31·9)
3, 1·0%† 
(0·0 to 2·1)¶
134, 21·4%* 
(0·1 to 70·3)
9, 2·8%† 
(1·0 to 4·6)
3, 7·3%* 
(0·9 to 36·0)
0, ·· 46, 8·9%* 
(0·3 to 27·9)
Malawi
44,45 2 442,  43·9%* 
(18·3 to 71·4)
6, 0·5%* 
(0·0 to 2·3)
113, 7·9%* 
(5·3 to 51·9)
26, 2·3%* 
(0·2 to 11·5)
300, 31·6%* 
(25·7 to 37·8)
16, 1·6%* 
(0·4 to 3·6)
8, 0·9%† 
(0·3 to 1·5)
19, 1·2%* 
(0·3 to 7·1)
Namibia
17 1 38,  71·7%‡ 
(57·7 to 83·2)
5, 9·4%‡ 
(3·1 to 20·7)
0, ·· 0, ·· 0, ·· 0, ·· 0, ·· 10, 18·9%‡ 
(9·4 to 32·0)
Nigeria
17,47,48,51,56–59 8 307,  30·9%* 
(19·8 to 43·2)
25, 1·9%* 
(0·2 to 5·5)
161, 12·6%* 
(5·4 to 22·3)
1, 0·2%† 
(0·0 to 0·5)¶
43, 3·0%* 
(0·3 to 8·6)
48, 2·2%* 
(0·2 to 6·3)
126, 13·4%* 
(8·3 to 19·5)
215, 27·6%* 
(11·7 to 47·1)
South Africa
17,64 2 392,  55·2%* 
(32·6 to 76·7)
49, 8·0%† 
(5·9 to 10·1)
21, 2·2%* 
(0·0 to 8·7)
30, 4·9%† 
(3·2 to 6·6)
10, 1·7%† 
(0·6 to 2·7)
21, 2·2%* 
(0·0 to 8·7)
21, 2·2%* 
(0·0 to 8·7)
75, 21·9%* 
(2·7 to 52·5)
Tanzania
17,67 2 58,  36·5%* 
(0·2 to 90·4)
6, 3·4%* 
(0·1 to 15·0)
5, 4·5%† 
(0·9 to 8·1)
0, ·· 0, ·· 43, 38·0%* 
(5·1 to 100·0)
5, 3·0%* 
(0·0 to 12·6)
11, 9·1%† 
(4·1 to 14·1)
Zambia
17,68 2 167,  60·5%* 
(27·8 to 88·6)
84, 21·5%* 
(10·5 to 35·0)
28, 4·0%* 
(0·3 to 19·3)
4, 1·4%† 
(0·2 to 2·7)
0, ·· 0, ·· 14, 2·5%* 
(0·0 to 9·7)
40, 12·0%† 
(8·5 to 15·5)
Zimbabwe
17 1 4,  20·0%‡ 
(5·7 to 43·7)
0, ·· 10, 50·0%‡ 
(27·2 to 72·8)
0, ·· 0, ·· 0, ·· 1, 5·0%‡ 
(0·1 to 24·9)
5, 25·0%‡ 
(8·7 to 49·1)
Total 35 1908, 34·9%* 
(26·6 to 43·6)
481, 9·1%* 
(5·4 to 13·7)
499, 8·6%* 
(4·9 to 13·3)
216, 1·9%* 
(0·6 to 3·9)
413, 3·3%* 
(1·2 to 6·3)
202, 2·6%* 
(1·0 to 4·7)
347, 7·8%* 
(4·8 to 11·5)
641, 15·4%* 
(10·8 to 20·6)
*Random-eﬀ  ects model. †Fixed-eﬀ  ects model. ‡Exact (Clopper–Pearson) estimate. §Two studies from the same reference were included. ¶Left-truncated estimate.
Table 3: G-type characterisation studies in sub-Saharan African countries, 1990–2009
Population in 
2005 of children 
<5 years*
Annual mortality rate 
in children <5 years 
(per 1000)†
Proportion of 
deaths caused 
by diarrhoea†
Proportion (95% CI) of diarrhoea 
due to rotavirus (hospital 
based)‡
Annual mortality rate (95% CI) 
due to rotavirus (per 100 000)
Annual number of deaths 
due to rotavirus (95% CI)
Benin
18 1 332 000 38·6 17·1% 29·1% (23·5–35·4) 191·9 (154·9–233·6) 2556 (2064 –3111)
Côte d’Ivoire
17 3 004 000 194·0 14·8% 28·4% (24·5–32·6) 194·6 (168·2–223·3) 5845 (5051–6709)
Kenya
41 5 948 000 30·2 16·5% 30·0% (28·0–32·1) 149·6 (139·7–159·9) 8898 (8308–9512)
Malawi
45 2 467 000 42·1 18·1% 39·2% (36·3–42·1) 298·7 (276·7–321·2) 7368 (6826–7924)
Nigeria
17,52,53 23 635 000 50·0 15·7% 38·3% (15·3–64·6) 301·0 (119·8–507·6) 71 144 (28 327–119 965)
South Africa
63 5 239 000 13·9 0·8% 55·3% (52·4–58·2) 6·2 (5·8–6.5) 323 (306–340)
Zambia
69 2 141 000 45·8 17·5% 23·9% (21·5–26·6) 192·0 (172·3–213·3) 4111 (3688–4566)
Total  126 836 000 41·4 16·6% 35·4% (27·3–43·9) 243·3 (187·6–301·7) 308 579 (237 972–382 672)
*United Nations population estimates.
16 †Data from WHO country proﬁ  les (http://www.who.int/countries/en/). ‡All estimates were calculated using Clopper–Pearson exact CIs, except for Nigeria where a 
random-effect model was used.
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continent.
6,9 The G8 serotype has been frequently 
detected in Africa since the mid-1990s, and represents 
the fourth most common genotype, whereas outside 
Africa it has seldom been detected.
6,9 
The two new licensed vaccines have proven their 
eﬃ   cacy mainly against the G1–G4 and G9, the most 
common serotypes in high-income countries, but our 
analysis shows that these serotypes only represent 68% 
of the circulating strains in sub-Saharan Africa. If the 
current vaccine formulation does not produce cross-
protection against other genotypes more prevalent in 
countries in sub-Saharan Africa, their eﬀ  ectiveness 
could be reduced in this setting. Therefore, these 
genotypes may need to be included in future vaccines 
in order for them to be eﬀ  ective in these regions.
73 New 
P–G strains could emerge as the result of mixed 
rotavirus infections that account for up to 8% of the 
samples (summary proportion). When mixed infections 
with distinct rotavirus strains occur, the gene segments 
may reassort independently, producing reassortant 
strains, which is an important source of viral 
diversity.
74 Investigation of future rotavirus vaccines 
should consider the geographical variation in the 
distribution of genotypes. In India, a vaccine that 
potentially protects against local strains is under 
development.
6
The key limitation of this review is that the results 
may not be representative of all countries in sub-
Saharan Africa. Data on disease burden and strain 
information was not available for many countries or 
did not meet the inclusion criteria for this analysis. 
Moreover, the included studies may not be 
representative of the country as a whole; none of the 
studies covered the whole country, and information on 
the representativeness of the sample was generally not 
given. Nevertheless, we tried to ensure that the most 
valid studies concerning the two objectives of this 
review were included through restrictive inclusion 
criteria. Another limitation is that mortality rate 
estimates are based on prevalence and not on incidence 
studies. Incidence studies are rare and are clearly 
needed for future research. 
Studies 
(n)
Summary proportion by P type
P[4] P[6] P[8] P[9] P[10] Mixed Untyped
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Botswana
17,19,20 3 1 1·8%* 
(0·0–4·8)†
13 18·2%‡ 
(2·9–42·5)
38 32·8%‡ 
(0·0–88·5)
0 .. 0 .. 5 5·2%‡ 
(0·1–22·8)
23 32·2%‡ 
(6·1–66·8)
Burkina Faso
17 1 0 .. 28 75·7%§ 
(58·8–88·2)
5 13·5%§ 
(4·5–28·8)
0 .. 0 .. 2 5·4%§ 
(0·7–18·2)
2 5·4%§ 
(0·7–18·2)
Cameroon
17 2 21 6·0%‡ 
(0·1–20·1)
10 15·4%‡ 
(10·6–82·4)
147 50·5%‡ 
(9·7–90·9)
4 2·2%* 
(0·2–4·1)
4 2·2%* 
(0·2–4·1)
0 .. 29 13·6%* 
(9·1–18·2)
Côte d’Ivoire
17,37 2 5 1·8%* 
(0·3–3·3)
87 28·8%‡ 
(14·0–46·4)
108 31·8%‡ 
(8·3–61·9)
1 0·4%* 
(0·0–1·2)†
0 .. 37 11·9%* 
(8·3–15·5)
74 23·8%* 
(19·1–28·6)
Ghana
17,26–29 5 101 15·9%‡ 
(3·7–34·5)
193 33·4%‡ 
(15·2–54·6)
272 28·3%‡ 
(6·0–58·9)
0 .. 4 0·8%* 
(0·1–1·5)
27 4·1%* 
(2·6–5·7)
61 9·2%* 
(4·5–15·5)
Guinea Bissau
32–34 3 65 18·8%* 
(14·7–22·9)
131 37·8%* 
(32·7–43·0)
32 7·8%‡ 
(2·7–15·2)
3 0·9%* 
(0·0–1·9)†
0 .. 65 20·7%‡ 
(3·1–48·1)
49 10·4%‡ 
(0·8–28·8)
Kenya
17,40 2 19 9·1%* 
(5·3–12·9)
56 25·6%* 
(19·8–31·3)
109 49·6%* 
(43·0–56·3)
0 .. 4 2·2%* 
(0·3–4·1)
0 .. 32 15·0%* 
(10·3–19·7)
Malawi
44,45 2 72 7·6%* 
(5·9–9·3)
262 27·8%‡ 
(18·5–38·3)
574 59·3%‡ 
(50·7–67·6)
0 .. 0 .. 12 1·3%‡ 
(0·0–4·1)
40 3·7%‡ 
(0·6–9·1)
Namibia
17 1 5 9·4%§ 
(3·1–20·7)
0 .. 38 71·7%§ 
(57·7–83·2)
0 .. 0 .. 0 .. 10 18·9%§ 
(9·4–32·0)
Nigeria
17,48,49,51,58 5 4 1·4%* 
(0·1–2·7)
121 38·6%‡ 
(26·6–51·4)
59 18·5%‡ 
(9·0–30·4)
1 0·8%* 
(0·0–1·8)†
0 .. 38 18·5%‡ 
(8·2–31·9)
98 26·6%‡ 
(8·0–51·1)
South Africa
17,62 2 61 10·4%‡ 
(2·4–23·0)
107 12·3%‡ 
(3·0–26·5)
420 52·0%‡ 
(33·4–70·4)
3 0·5%* 
(0·0–0·9)†
3 0·5%* 
(0·0–0·9)†
29 4·0%* 
(2·6–5·4)
112 19·9%‡ 
(3·2–46·0)
Tanzania
17,67 2 1 1·0%* 
(0·0–2·7)†
27 16·2%‡ 
(0·2–49·7)
82 68·3%‡ 
(35·4–93·2)
0 .. 0 .. 0 .. 18 14·5%* 
(8·4–20·6)
Zambia
17,68 2 20 13·2%* 
(7·9–18·5)
62 21·9%‡ 
(10·9–93·3)
65 49·1%‡ 
(2·8–96·6)
0 .. 0 .. 0 .. 10 6·9%* 
(2·9–10·9)
Zimbabwe
17 1 0 .. 10 50·0%§ 
(27·2–72·8)
4 20·0%§ 
(5·7–43·7)
0 .. 0 .. 1 5·0%§ 
(0·1–24·9)
5 25·0%§ 
(8·7–49·1)
Total 33 375 7·3%‡ 
(4·9–10·1)
1107 27·5%‡ 
(21·2–34·3)
1953 35·5%‡ 
(27·1–44·4)
12 0·4%* 
(0·2–0·6)
15 0·4%* 
(0·2–0·6)
216 5·6%‡ 
(3·5–8·2)
563 15·5%‡ 
(11·4–20·0)
*Fixed-eﬀ  ects model. †Left-truncated estimate. ‡Random-eﬀ  ects model. §Exact (Clopper–Pearson) estimate.
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WHO has recently recommended the inclusion of 
rotavirus vaccine worldwide, based principally on the 
additional preliminary results of vaccine eﬃ   cacy 
studies in two African countries (Malawi and South 
Africa).
75 Concerns about the safety and feasibility of 
the introduction of the rotavirus vaccine in low-income 
countries have been commented on elsewhere,
24,76,77 and 
include the previous poor responses of live oral vaccines 
observed in these settings,
78,79 problems delivering the 
recommended number of doses, timing of ﬁ  rst dose 
administration, and the risk of intussusception if 
given to children older than recommended by 
manufacturers.
80
Documentation on the burden of disease and the 
circulating strains is essential to assess the eﬀ  ectiveness 
of the vaccines and the impact of their future 
introduction. To assess the burden of disease and the 
circulating strains, regional surveillance by standardised 
methods, which enable comparison between countries, 
should be either reinforced or developed. WHO 
strongly recommends sentinel surveillance before the 
introduction of the vaccines to monitor vaccine impact 
(although absence of surveillance should not stop 
vaccine introduction).
75 These sentinel surveillance 
systems should ideally measure mortality and 
morbidity, both hospital and community based, and 
the strains circulating, by RT-PCR based on new 
primers and standardised techniques. The African 
Regional Network–Rotavirus Surveillance Network is 
currently doing hospital-based surveillance of rotavirus 
disease in children aged under 5 years in 14 African 
countries with the support from WHO,
81 US Centers 
for Disease Control and Prevention,
82 and PATH’s 
rotavirus vaccine programme. This critical eﬀ  ort should 
be expanded to other countries. After the 
implementation of the vaccines, adapted surveillance 
will ideally allow the detection of the impact of rotavirus 
vaccines on the burden of disease, possible adverse 
events, and the emergence of new strains as rotaviruses 
evolve. 
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